Stephanie A. Irving
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephanie A. Irving has a total of 509 co-authors. Here are the top co-authors by number of shared publications:
- Allison L. Naleway
Kaiser Permanente Center for Health Research, Portland, Oregon
24 shared publications - Edward A. Belongia
Marshfield Clinic Research Institute , Marshfield, Wisconsin
23 shared publications Allison L. Naleway
Kaiser Permanente Center for Health Research, Portland, OR, USA
20 shared publicationsNicola P. Klein
Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA
17 shared publicationsLisa A. Jackson
Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
13 shared publications- David K. Shay
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Influenza Division, Atlanta, GA, USA
12 shared publications
Latest Publications
- 1 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8) , ofag473
Influenza Vaccine Effectiveness Against Influenza-Associated Hospitalizations and Emergency Department or Urgent Care Encounters Among Children and Adults—VISION, United States, 2024–2025 Season
Background: The 2024–2025 influenza season was the most severe in the United States (US) since 2017–2018, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. Methods: Using electronic healthcare encounter data from 7 VISION sites in 8 US states, we evaluated influenza VE against influenza-associated hospitalizations and emergency department or urgent care (ED/UC) encounters from October 2024 to April 2025 among children aged 6 months–17 years and adults aged ≥18 years. Using a test-negative, case-control design, we compared the odds of influenza vaccination between acute respiratory illness encounters with a positive (cases) versus negative (controls) test for influenza by molecular assay, adjusting for confounders. Results: Analyses included 108 618 encounters (5764 hospitalizations and 102 854 ED/UC encounters) among children and 309 483 encounters (76 072 hospitalizations and 233 411 ED/UC encounters) among adults. Among children across care settings, 17.0% (6097/35 765) of cases versus 29.4% (21 449/72 853) of controls were vaccinated. Among adults, 28.2% (21 832/77 477) of cases versus 44.2% (102 560/232 006) of controls were vaccinated. VE was 51% (95% confidence interval [95% CI]: 41%–60%) against influenza-associated hospitalizations and 54% (95% CI: 52%–55%) against influenza-associated ED/UC encounters among children. VE was 43% (95% CI: 41%–46%) against influenza-associated hospitalizations and 49% (95% CI: 47%–50%) against influenza-associated ED/UC encounters among adults. Conclusions: Influenza vaccination provided protection against influenza-associated hospitalizations and ED/UC encounters among children and adults in the US during the severe 2024–2025 influenza season. These findings support influenza vaccination as an important tool to reduce influenza.
- 1 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8) , ofag473
Influenza Vaccine Effectiveness Against Influenza-Associated Hospitalizations and Emergency Department or Urgent Care Encounters Among Children and Adults—VISION, United States, 2024–2025 Season
Background: The 2024–2025 influenza season was the most severe in the United States (US) since 2017–2018, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. Methods: Using electronic healthcare encounter data from 7 VISION sites in 8 US states, we evaluated influenza VE against influenza-associated hospitalizations and emergency department or urgent care (ED/UC) encounters from October 2024 to April 2025 among children aged 6 months–17 years and adults aged ≥18 years. Using a test-negative, case-control design, we compared the odds of influenza vaccination between acute respiratory illness encounters with a positive (cases) versus negative (controls) test for influenza by molecular assay, adjusting for confounders. Results: Analyses included 108 618 encounters (5764 hospitalizations and 102 854 ED/UC encounters) among children and 309 483 encounters (76 072 hospitalizations and 233 411 ED/UC encounters) among adults. Among children across care settings, 17.0% (6097/35 765) of cases versus 29.4% (21 449/72 853) of controls were vaccinated. Among adults, 28.2% (21 832/77 477) of cases versus 44.2% (102 560/232 006) of controls were vaccinated. VE was 51% (95% confidence interval [95% CI]: 41%–60%) against influenza-associated hospitalizations and 54% (95% CI: 52%–55%) against influenza-associated ED/UC encounters among children. VE was 43% (95% CI: 41%–46%) against influenza-associated hospitalizations and 49% (95% CI: 47%–50%) against influenza-associated ED/UC encounters among adults. Conclusions: Influenza vaccination provided protection against influenza-associated hospitalizations and ED/UC encounters among children and adults in the US during the severe 2024–2025 influenza season. These findings support influenza vaccination as an important tool to reduce influenza.
- Open Access
- 7 June 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2681305
Retrospective cohort study of mRNA COVID-19 vaccine-associated enhanced disease in the Vaccine Safety Datalink, 2021–23
Vaccine-associated enhanced disease (VAED) was recognized as a theoretical risk when COVID-19 vaccines were authorized. Epidemiologic data can identify a signal for VAED if vaccine effectiveness (VE) is negative for preventing serious illness. In 2021, we initiated a cohort study to examine VAED indirectly by estimating VE against COVID-19 hospitalization and severe illness in the Vaccine Safety Datalink. The study cohort included VSD enrollees who were age-eligible to receive mRNA COVID-19 vaccine from February 2021-March 2023. Outcomes were initial COVID-19-associated hospital admission and severe in-hospital complications (acute respiratory distress or failure). VE was estimated by dose, variant period, and for early (14–119 d) and late (≥120 d) post-vaccination periods. VE was defined as 100*(1- adjusted hazard ratio). Relative VE (rVE) was estimated for bivalent vaccine versus ≥2 monovalent vaccine doses. The hospitalization analysis included all 16,027 enrollees with COVID-19 hospitalization and a 5% random sample of non-hospitalized enrollees who contributed person-time (n = 138,238). Two-dose original monovalent VE against hospitalization exceeded 90% in most age groups during the pre-Delta and Delta periods. VE was lower during the Omicron period. During the Omicron BA.2/BA.4/BA.5/XBB period, a fourth monovalent dose or bivalent dose generated VE of 59%–78% across age groups with modest waning. rVE was 48%–60% across age groups for bivalent vaccine vs. ≥2 original monovalent doses. Overall, the results were similar for VE against severe in-hospital complication. In conclusion, there was no signal for VAED during any variant period or for any specific dose of monovalent or bivalent vaccine.
- 7 June 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2681305
Open AccessRetrospective cohort study of mRNA COVID-19 vaccine-associated enhanced disease in the Vaccine Safety Datalink, 2021–23
Vaccine-associated enhanced disease (VAED) was recognized as a theoretical risk when COVID-19 vaccines were authorized. Epidemiologic data can identify a signal for VAED if vaccine effectiveness (VE) is negative for preventing serious illness. In 2021, we initiated a cohort study to examine VAED indirectly by estimating VE against COVID-19 hospitalization and severe illness in the Vaccine Safety Datalink. The study cohort included VSD enrollees who were age-eligible to receive mRNA COVID-19 vaccine from February 2021-March 2023. Outcomes were initial COVID-19-associated hospital admission and severe in-hospital complications (acute respiratory distress or failure). VE was estimated by dose, variant period, and for early (14–119 d) and late (≥120 d) post-vaccination periods. VE was defined as 100*(1- adjusted hazard ratio). Relative VE (rVE) was estimated for bivalent vaccine versus ≥2 monovalent vaccine doses. The hospitalization analysis included all 16,027 enrollees with COVID-19 hospitalization and a 5% random sample of non-hospitalized enrollees who contributed person-time (n = 138,238). Two-dose original monovalent VE against hospitalization exceeded 90% in most age groups during the pre-Delta and Delta periods. VE was lower during the Omicron period. During the Omicron BA.2/BA.4/BA.5/XBB period, a fourth monovalent dose or bivalent dose generated VE of 59%–78% across age groups with modest waning. rVE was 48%–60% across age groups for bivalent vaccine vs. ≥2 original monovalent doses. Overall, the results were similar for VE against severe in-hospital complication. In conclusion, there was no signal for VAED during any variant period or for any specific dose of monovalent or bivalent vaccine.
- Open Access
Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults — United States, 2024–25 season
Background: The 2024–25 influenza season was the most severe in the United States (US) since 2017–18, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. Methods: Using electronic healthcare encounter data from eight US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated hospitalizations and emergency department or urgent care (ED/UC) encounters from October 2024–April 2025 among children aged 6 months–17 years and adults aged ≥18 years. Using a test-negative, case-control design, we compared the odds of influenza vaccination between acute respiratory illness (ARI) encounters with a positive (cases) versus negative (controls) test for influenza by molecular assay, adjusting for confounders. Results: Analyses included 108,618 encounters (5,764 hospitalizations and 102,854 ED/UC encounters) among children and 309,483 encounters (76,072 hospitalizations and 233,411 ED/UC encounters) among adults. Among children across care settings, 17.0% (6,097/35,765) of cases versus 29.4% (21,449/72,853) of controls were vaccinated. Among adults, 28.2% (21,832/77,477) of cases versus 44.2% (102,560/232,006) of controls were vaccinated. VE was 51% (95% confidence interval [95% CI]: 41–60%) against influenza-associated hospitalizations and 54% (95% CI: 52–55%) against influenza-associated ED/UC encounters among children. VE was 43% (95% CI: 41–46%) against influenza-associated hospitalizations and 49% (95% CI: 47–50%) against influenza-associated ED/UC encounters among adults. Conclusions: Influenza vaccination provided protection against influenza-associated hospitalizations and ED/UC encounters among children and adults in the US during the severe 2024–25 influenza season. These findings support influenza vaccination as an important tool to reduce influenza-associated disease. Brief Summary: During the 2024–25 influenza season, influenza vaccination provided protection against influenza-associated hospitalizations (43–51%) and emergency department or urgent care encounters (49–54%) among children and adults in the United States.
Open AccessInfluenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults — United States, 2024–25 season
Background: The 2024–25 influenza season was the most severe in the United States (US) since 2017–18, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. Methods: Using electronic healthcare encounter data from eight US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated hospitalizations and emergency department or urgent care (ED/UC) encounters from October 2024–April 2025 among children aged 6 months–17 years and adults aged ≥18 years. Using a test-negative, case-control design, we compared the odds of influenza vaccination between acute respiratory illness (ARI) encounters with a positive (cases) versus negative (controls) test for influenza by molecular assay, adjusting for confounders. Results: Analyses included 108,618 encounters (5,764 hospitalizations and 102,854 ED/UC encounters) among children and 309,483 encounters (76,072 hospitalizations and 233,411 ED/UC encounters) among adults. Among children across care settings, 17.0% (6,097/35,765) of cases versus 29.4% (21,449/72,853) of controls were vaccinated. Among adults, 28.2% (21,832/77,477) of cases versus 44.2% (102,560/232,006) of controls were vaccinated. VE was 51% (95% confidence interval [95% CI]: 41–60%) against influenza-associated hospitalizations and 54% (95% CI: 52–55%) against influenza-associated ED/UC encounters among children. VE was 43% (95% CI: 41–46%) against influenza-associated hospitalizations and 49% (95% CI: 47–50%) against influenza-associated ED/UC encounters among adults. Conclusions: Influenza vaccination provided protection against influenza-associated hospitalizations and ED/UC encounters among children and adults in the US during the severe 2024–25 influenza season. These findings support influenza vaccination as an important tool to reduce influenza-associated disease. Brief Summary: During the 2024–25 influenza season, influenza vaccination provided protection against influenza-associated hospitalizations (43–51%) and emergency department or urgent care encounters (49–54%) among children and adults in the United States.
- 13 November 2025
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 156 (6)
Effectiveness of 2023–2024 COVID-19 Vaccines in Children in the United States
- 13 November 2025
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 156 (6)
Effectiveness of 2023–2024 COVID-19 Vaccines in Children in the United States
- Open Access
- 6 August 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 49
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis
- 6 August 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 49
Open AccessEffectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis
- 6 May 2025
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 155 (6)
Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023–2024
BACKGROUND AND OBJECTIVES: In 2023, the Advisory Committee on Immunization Practices recommended either Abrysvo, a vaccine administered during pregnancy, or nirsevimab, a monoclonal antibody administered to infants after birth, to protect infants from respiratory syncytial virus (RSV). Our objective was to assess the proportion of infants immunized against RSV through antenatal RSV vaccination or receipt of nirsevimab among linked pregnancy-infant dyads. METHODS: Using data from 10 Vaccine Safety Datalink health systems and a validated algorithm, we identified pregnant women aged 12 to 55 years with a live birth of 32 weeks’ gestation or more from September 22, 2023, through March 31, 2024. We identified RSV vaccination using electronic health records supplemented with immunization information system (registry) data. Among infants from eligible pregnancies, we identified nirsevimab administered through March 31, 2024. We assessed infant RSV immunization, defined as exposure to antenatal RSV vaccination or receipt of nirsevimab, stratified by race and ethnicity, age, and birth month. RESULTS: A total of 36 949 eligible infants were included from 43 722 pregnancies. Overall, 72% of infants were immunized against RSV; estimates were highest among infants born to non-Hispanic (NH) Asian mothers (84%). Disparities were identified by race, with 60% coverage among infants born to NH Black or NH Middle Eastern or North African mothers. Coverage was 59% to 78% by birth month, with nirsevimab more commonly administered to infants born earlier in the season. CONCLUSIONS: In this population of infants, 72% were immunized against RSV. Although overall coverage was high, disparities in immunization by race and ethnicity are a call to action.
- 6 May 2025
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 155 (6)
Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023–2024
BACKGROUND AND OBJECTIVES: In 2023, the Advisory Committee on Immunization Practices recommended either Abrysvo, a vaccine administered during pregnancy, or nirsevimab, a monoclonal antibody administered to infants after birth, to protect infants from respiratory syncytial virus (RSV). Our objective was to assess the proportion of infants immunized against RSV through antenatal RSV vaccination or receipt of nirsevimab among linked pregnancy-infant dyads. METHODS: Using data from 10 Vaccine Safety Datalink health systems and a validated algorithm, we identified pregnant women aged 12 to 55 years with a live birth of 32 weeks’ gestation or more from September 22, 2023, through March 31, 2024. We identified RSV vaccination using electronic health records supplemented with immunization information system (registry) data. Among infants from eligible pregnancies, we identified nirsevimab administered through March 31, 2024. We assessed infant RSV immunization, defined as exposure to antenatal RSV vaccination or receipt of nirsevimab, stratified by race and ethnicity, age, and birth month. RESULTS: A total of 36 949 eligible infants were included from 43 722 pregnancies. Overall, 72% of infants were immunized against RSV; estimates were highest among infants born to non-Hispanic (NH) Asian mothers (84%). Disparities were identified by race, with 60% coverage among infants born to NH Black or NH Middle Eastern or North African mothers. Coverage was 59% to 78% by birth month, with nirsevimab more commonly administered to infants born earlier in the season. CONCLUSIONS: In this population of infants, 72% were immunized against RSV. Although overall coverage was high, disparities in immunization by race and ethnicity are a call to action.
- 4 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (3) , 667-678
Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States
Background: The 2023–2024 influenza season had predominant influenza A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses cocirculated. Seasonal influenza vaccine strains were well-matched to these viruses. Methods: Using healthcare encounters data from health systems in 8 US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated medical encounters from October 2023 to April 2024. Using a test-negative design, we compared the odds of vaccination between patients with an acute respiratory illness who tested positive (cases) versus negative (controls) for influenza by molecular assay, adjusting for confounders. VE was stratified by age group, influenza type (overall, influenza A, influenza B), and care setting (hospitalization, emergency department or urgent care [ED/UC] encounter). Results: Overall, 74 000 encounters in children and adolescents aged 6 months–17 years (3479 hospitalizations, 70 521 ED/UC encounters) and 267 606 in adults aged ≥18 years (66 828 hospitalizations, 200 778 ED/UC encounters) were included. Across care settings, among children and adolescents, 15% (2758/17 833) of cases versus 32% (18 240/56 167) of controls had received vaccination. Among adults, 25% (11 632/46 614) of cases versus 44% (97 811/220 992) of controls across care settings had received vaccination. VE was 58% (95% confidence interval [95% CI], 44–69) against hospitalization and 58% (95% CI, 56–60) against ED/UC encounters for children and adolescents, and 39% (95% CI, 35–43) against hospitalization and 47% (95% CI, 46–49) against ED/UC encounters for adults. Across age groups, VE was higher against influenza B than influenza A. Conclusions: Influenza vaccines provided protection against influenza-associated illness across health care settings and age groups during the 2023–2024 influenza season.
- 4 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (3) , 667-678
Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States
Background: The 2023–2024 influenza season had predominant influenza A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses cocirculated. Seasonal influenza vaccine strains were well-matched to these viruses. Methods: Using healthcare encounters data from health systems in 8 US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated medical encounters from October 2023 to April 2024. Using a test-negative design, we compared the odds of vaccination between patients with an acute respiratory illness who tested positive (cases) versus negative (controls) for influenza by molecular assay, adjusting for confounders. VE was stratified by age group, influenza type (overall, influenza A, influenza B), and care setting (hospitalization, emergency department or urgent care [ED/UC] encounter). Results: Overall, 74 000 encounters in children and adolescents aged 6 months–17 years (3479 hospitalizations, 70 521 ED/UC encounters) and 267 606 in adults aged ≥18 years (66 828 hospitalizations, 200 778 ED/UC encounters) were included. Across care settings, among children and adolescents, 15% (2758/17 833) of cases versus 32% (18 240/56 167) of controls had received vaccination. Among adults, 25% (11 632/46 614) of cases versus 44% (97 811/220 992) of controls across care settings had received vaccination. VE was 58% (95% confidence interval [95% CI], 44–69) against hospitalization and 58% (95% CI, 56–60) against ED/UC encounters for children and adolescents, and 39% (95% CI, 35–43) against hospitalization and 47% (95% CI, 46–49) against ED/UC encounters for adults. Across age groups, VE was higher against influenza B than influenza A. Conclusions: Influenza vaccines provided protection against influenza-associated illness across health care settings and age groups during the 2023–2024 influenza season.
- 18 August 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (8) , e5863
Lack of Evidence for Vaccine‐Associated Enhanced Disease From COVID‐19 Vaccines Among Adults in the Vaccine Safety Datalink
Purpose: Vaccine‐associated enhanced disease (VAED) is a theoretical concern with new vaccines, although trials of authorized vaccines against SARS‐CoV‐2 have not identified markers for VAED. The purpose of this study was to detect any signals for VAED among adults vaccinated against coronavirus disease 2019 (COVID‐19).Methods: In this cross‐sectional study, we assessed COVID‐19 severity as a proxy for VAED among 400 adults hospitalized for COVID‐19 from March through October 2021 at eight US healthcare systems. Primary outcomes were admission to an intensive care unit (ICU) and severe illness (score ≥6 on the World Health Organization [WHO] Clinical Progression Scale). We compared the risk of outcomes among those who had completed a COVID‐19 vaccine primary series versus those who were unvaccinated. We incorporated inverse propensity weights for vaccination status in a doubly robust regression model to estimate the causal average treatment effect.Results: The causal risk ratio in vaccinated versus unvaccinated was 0.36 (95% confidence interval [CI], 0.15–0.94) for ICU admission and 0.46 (95% CI, 0.25–0.76) for severe illness.Conclusion: Among hospitalized patients, reduced disease severity in those vaccinated against COVID‐19 supports the absence of VAED.
- 18 August 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (8) , e5863
Lack of Evidence for Vaccine‐Associated Enhanced Disease From COVID‐19 Vaccines Among Adults in the Vaccine Safety Datalink
Purpose: Vaccine‐associated enhanced disease (VAED) is a theoretical concern with new vaccines, although trials of authorized vaccines against SARS‐CoV‐2 have not identified markers for VAED. The purpose of this study was to detect any signals for VAED among adults vaccinated against coronavirus disease 2019 (COVID‐19).Methods: In this cross‐sectional study, we assessed COVID‐19 severity as a proxy for VAED among 400 adults hospitalized for COVID‐19 from March through October 2021 at eight US healthcare systems. Primary outcomes were admission to an intensive care unit (ICU) and severe illness (score ≥6 on the World Health Organization [WHO] Clinical Progression Scale). We compared the risk of outcomes among those who had completed a COVID‐19 vaccine primary series versus those who were unvaccinated. We incorporated inverse propensity weights for vaccination status in a doubly robust regression model to estimate the causal average treatment effect.Results: The causal risk ratio in vaccinated versus unvaccinated was 0.36 (95% confidence interval [CI], 0.15–0.94) for ICU admission and 0.46 (95% CI, 0.25–0.76) for severe illness.Conclusion: Among hospitalized patients, reduced disease severity in those vaccinated against COVID‐19 supports the absence of VAED.